The benefit observed in patients with Waldenstrom’s macroglobulinemia treated with Imbruvica (ibrutinib) plus Rituxan (rituximab), compared with placebo and Rituxan, focused on survival and response to the treatment, both of which occurred despite prior treatment and genotypes.
Read More
High-Dose Imetelstat Could Offer Patients with High-Risk Myelofibrosis Improved Overall Survival
December 5th 2020An analysis of the phase 2 study IMbark shows how imetelstat can offer patients with high-risk myelofibrosis multiple clinical benefits, setting the stage for an expanded phase 3 trial.
Read More
Evolving Standards and Heated Debates in the Treatment of Newly Diagnosed Multiple Myeloma
December 4th 2020Evolving standards of care in newly diagnosed multiple myeloma (MM) have given patients a wider variety of possibilities but can also be disconcerting. In a presentation during CURE®’s Educated Patient® Multiple Myeloma Summit, Dr. Clifton Mo, of Dana-Farber Cancer Institute, explores the treatment landscape and breaks down what these different options can offer patients.
Read More
Susan G. Komen Greater New York City 4th Annual Patient Navigation Town Hall Livestream
June 22nd 2020In partnership with CURE®, Susan G. Komen Greater New York City hosts its 4th Annual Patient Navigation Town Hall "Empowering and Mobilizing Our Patient Navigation Workforce". Oncologists, community health workers and patient navigators will get together on June 23rd, via webinar, to discuss the impact of the COVID-19 pandemic on the cancer landscape and how professionals and patients can navigate the fallout moving forward.
Watch
Exercise Programs Improve Outcomes for Patients with Breast Cancer
March 8th 2020At the 37th Annual Miami Breast Cancer Conference Dr. Jean-Bernard Durand discussed data that showed how prescribed and personalized exercise programs can improve outcomes for patients with cancer who already face a high risk of cardiovascular disease.
Read More